"Benzodioxoles" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Compounds based on benzene fused to oxole. They can be formed from methylated CATECHOLS such as EUGENOL.
| Descriptor ID |
D052117
|
| MeSH Number(s) |
D03.383.246.118 D03.633.100.115
|
| Concept/Terms |
Benzodioxoles- Benzodioxoles
- 1,3-Dioxindans
- 1,3 Dioxindans
- Methylenedioxybenzenes
- 1,3-Dioxaindans
- 1,3 Dioxaindans
|
Below are MeSH descriptors whose meaning is more general than "Benzodioxoles".
Below are MeSH descriptors whose meaning is more specific than "Benzodioxoles".
This graph shows the total number of publications written about "Benzodioxoles" by people in this website by year, and whether "Benzodioxoles" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2006 | 1 | 0 | 1 |
| 2010 | 1 | 0 | 1 |
| 2012 | 1 | 0 | 1 |
| 2017 | 1 | 0 | 1 |
| 2020 | 2 | 1 | 3 |
| 2021 | 0 | 1 | 1 |
| 2022 | 0 | 1 | 1 |
| 2025 | 2 | 0 | 2 |
| 2026 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Benzodioxoles" by people in Profiles.
-
Fyn-Saracatinib Complex Structure Reveals an Active State-like Conformation. Int J Mol Sci. 2026 Jan 23; 27(3).
-
Impact of elexacaftor/tezacaftor/ivacaftor on biomarkers of cystic fibrosis hepatobiliary involvement in the PUSH study. J Pediatr Gastroenterol Nutr. 2026 Feb; 82(2):350-357.
-
Gastrointestinal Burden in Patients With Pancreatic Insufficient Cystic Fibrosis Before and After Elexacaftor/Tezacaftor/Ivacaftor Use. Pancreas. 2025 Nov-Dec 01; 54(10):e858-e862.
-
Saracatinib, a Selective Src Kinase Inhibitor, Blocks Fibrotic Responses in Preclinical Models of Pulmonary Fibrosis. Am J Respir Crit Care Med. 2022 12 15; 206(12):1463-1479.
-
Papilledema and hypervitaminosis A after elexacaftor/tezacaftor/ivacaftor for cystic fibrosis. Can J Ophthalmol. 2022 02; 57(1):e6-e10.
-
A phase 3, randomized, double-blind, parallel-group study to evaluate tezacaftor/ivacaftor in people with cystic fibrosis heterozygous for F508del-CFTR and a gating mutation. J Cyst Fibros. 2021 03; 20(2):234-242.
-
Lumacaftor/ivacaftor therapy fails to increase insulin secretion in F508del/F508del CF patients. J Cyst Fibros. 2021 03; 20(2):333-338.
-
Trikafta and Psychopathology in Cystic Fibrosis: A Case Report. Psychosomatics. 2020 Nov - Dec; 61(6):735-738.
-
Lumacaftor/ivacaftor in patients with cystic fibrosis and advanced lung disease homozygous for F508del-CFTR. J Cyst Fibros. 2018 03; 17(2):228-235.
-
IGFBP2/FAK pathway is causally associated with dasatinib resistance in non-small cell lung cancer cells. Mol Cancer Ther. 2013 Dec; 12(12):2864-73.